Mus81 plays an integral role in the maintenance of genome stability and DNA repair in mammalian cells. Deficiency of Mus81 in human and mouse cells results in hypersensitivity to interstrand cross-linking (ICL) agents and elevated levels of genomic instability. Furthermore, Mus81-mutant mice are susceptible to spontaneous lymphomas. The role of cellular checkpoints in mediating the phenotypes observed in Mus81-deficient cells and mice is currently unknown. In this study, we have observed increased activation of p53 in Mus81 Significantly, we show that loss of even a single allele of Mus81 drastically modifies the tumor spectrum of p53-mutant mice and increases their predisposition to developing sarcomas. Our results reveal a key role for p53 in mediating the response to spontaneous and ICL-induced DNA damage that occurs in the absence of Mus81. Furthermore, our data show that loss of Mus81, in addition to p53, is a key step in sarcoma development.
Introduction
DNA interstrand cross-linking (ICL) agents, such as cisplatin and mitomycin C (MMC), are commonly used as antitumor agents in the treatment of a broad spectrum of cancers (1) . The therapeutic use of these drugs has generated increased interest in understanding the mechanisms by which ICLs are repaired in mammalian cells. ICL agents disrupt replication of the genome by inducing the formation of stalled replication forks, which, in turn, can collapse into broken forks that can lead to double-strand breaks (DSB) and chromosomal rearrangements (2) . ICL agents also interfere with critical cellular processes, such as transcription and recombination (3) . Yeast and bacterial studies have shown that both nucleotide excision repair and homologous recombination pathways are involved in ICL repair, but the mechanisms of mammalian ICL and stalled replication fork repair remain poorly characterized (4) (5) (6) (7) .
Mus81 (methyl methanesulfonate, UV sensitive, clone 81) was first identified in yeast as a member of the XPF family of endonucleases that physically interacts with the cell cycle checkpoint protein Cds1 (yeast homologue of mammalian Chk2) and the DNA repair protein Rad54 (8, 9) . Studies in yeast identified that Mus81 and its binding partner Eme1 formed a DNA structurespecific endonuclease (10) (11) (12) (13) . Yeast mutants of Mus81 were found to be sensitive to DNA-damaging agents that induce stalled replication forks but not DSBs (8, 9) . Meiotic defects in Schizosaccharomyces pombe mutants for Mus81 suggested that the Mus81-Eme1 endonuclease plays a key role in Holliday junction resolution (9) . Subsequent in vitro studies indicated that the yeast Mus81-Eme1 endonuclease is involved in the resolution of nicked Holliday junctions that may arise during recombination and repair processes. However, recent studies have indicated that the mammalian Mus81-Eme1 endonuclease preferentially cleaves stalled replication fork intermediates and has weak Holliday junction resolution activity (14) (15) (16) (17) . Furthermore, Mus81
À/À mice were found to be fertile, indicating that mammalian Mus81 is dispensable for the processing of Holliday junctions that may arise during meiosis (18, 19) . Cellular phenotypes of Mus81-deficient murine and human cells include exquisite sensitivity to ICL agents and elevated levels of spontaneous and MMC-induced genomic instability (18) (19) (20) . Importantly, our previous study showed that Mus81 +/À and Mus81 À/À mice spontaneously develop tumors, thus establishing Mus81 as a novel haploinsufficient tumor suppressor gene (18) . The mechanisms underlying the ICL sensitivity of Mus81-deficient cells have not yet been elucidated but may involve the activation of p53-dependent or p53-independent cellular checkpoints. Moreover, the role that p53 plays in suppressing the genome instability and tumors associated with Mus81 deficiency still remains to be addressed. In this study, we have generated double-knockout Mus81
À/À mice and addressed the effect of dual loss of p53 and Mus81 on development, DNA damage responses, genomic instability, and cancer. Our data show that p53 inactivation rescues the ICL sensitivity of Mus81-deficient cells at the expense of increased genomic instability. were in a mixed 129/J Â C57BL/6 genetic background and were genotyped by PCR (primer sequences and PCR conditions available on request). All experiments were done in compliance with the Ontario Cancer Institute animal care committee guidelines. Flow cytometry. Thymocytes, spleen, lymph nodes, and bone marrow cells were harvested from 8-to 12-week-old mice and stained with the following monoclonal antibodies (PharMingen): anti-CD4, anti-CD8, antiThy-1, anti-B220, anti-TCRah, anti-CD43, and anti-IgM. Fluorescenceactivated cell sorting (FACS) analyses were done using a FACSCalibur (Becton Dickinson).
Proliferation assay. For proliferation in response to T-cell stimuli, lymph nodes were isolated and 5 Â 10 5 cells were placed into roundbottomed 96-well plates in culture medium (RPMI 1640, 10% FCS, and 1% h-mercaptoethanol) and stimulated in triplicate with soluble anti-CD3 (5 Ag/mL) with or without anti-CD28 (1 Ag/mL) or interleukin-2 (IL-2; 50 units/mL). Cells were pulsed for the last 18 h with 1 ACi [ 3 H]thymidine (Amersham) per well and harvested at 48 and 72 h after treatment. Similarly, proliferation of B cells was assessed using 5 Â 10 5 splenocytes stimulated with anti-IgM (20 Ag/mL; Jackson ImmunoResearch) with or without anti-CD40 (5 Ag/mL; PharMingen) and lipopolysaccharide (LPS; 10 Ag/mL; Sigma).
Cell cycle analysis. Peripheral T lymphocytes were grown on platebound anti-CD3 and culture medium for 24 h followed by a 1-day culture in the presence of murine IL-2 (50 units/mL). The activated cells were treated with 0.5 Ag/mL MMC (Sigma) for 18 h. Cells were spun down and washed thrice with PBS and resuspended in fresh medium and cultured for an additional 18 h. Cells were fixed in 70% ethanol, and DNA was stained with 5 Ag/mL propidium iodide (Sigma) as described previously (21) .
Carboxyfluorescein diacetate succinimidyl ester staining. Peripheral T lymphocytes were stained with 5 Amol/L carboxyfluorescein diacetate succinimidyl ester (CFSE) and then activated with plate-bound anti-CD3 and culture medium for 24 h followed by a 1-day culture in the presence of murine IL-2 (50 units/mL). Untreated and 0.1 Ag/mL MMC-treated lymphocytes were grown for an additional 72 h. Cells were analyzed by flow cytometry to determine CFSE levels, and population values were determined using FlowJo analysis software (Tree Star).
Western blot analysis. Mouse embryonic fibroblasts (MEF) were plated on 10-cm plates at 30% to 40% confluency and cultured in the presence of 0 to 25 Ag/mL of MMC for 0 to 24 h. Protein cell extracts were prepared using 3% NP40 lysis buffer, and Western blots were done using rabbit polyclonal anti-p53 antibody (FL-393, 1:200 dilution; Santa Cruz Biotechnology), rabbit polyclonal anti-phosphorylated p53 (Ser
15
; 1:200 dilution; Cell Signaling), an affinity-purified rabbit polyclonal antibody raised against amino acids 190 to 211 of murine Mus81 (1:500 dilution), antitubulin (1:1,000 dilution; Sigma), and antiactin (1:1,000 dilution; Sigma).
Genomic instability analysis. Splenocytes were harvested from mice of 8 to 12 weeks of age and cultured in medium containing 10 Ag/mL LPS for 48 h in the presence or absence of MMC (40 ng/mL). Cells were then incubated with colcemid (0.1 Ag/mL) for 4 h, harvested, and treated with hypotonic buffer (0.075 mol/L KCl) at 37jC for 15 min. After fixation in icecold methanol/acetic acid (3:1) buffer, cells were dropped onto glass slides and stained with 4 ¶,6-diamidino-2-phenylindole (DAPI; Sigma) and chromosome number and gross chromosomal rearrangements were determined for a minimum of 60 metaphase spreads per cell type as described previously (18) .
Histology. Tumor and normal tissue paraffin sections were evaluated by H&E staining in conjunction with anti-Ki-67, anti-CD31, anti-CD3, and anti-B220 staining of adjacent sections as described previously (21) .
Bone marrow colony forming assay. Bone marrow cells were derived from femurs of 6-week-old mice. Bones were isolated and flushed with culture medium. Cells were seeded on 35-mm culture dishes at a density of 1 Â 10 5 /mL in MethoCult GF M3434 medium (Stemcell Technologies, Inc.). MMC (0-40 ng/mL) was added to the cell suspensions just before plating. Colonies were counted 10 days after plating.
;-Irradiation sensitivity. T lymphocytes were irradiated with 0, 2, or 4 Gy. Viability was assessed 12 h after irradiation by doing 7-aminoactinomycin D (7-AAD) staining (Sigma).
Results

Mus81
À/À cells express elevated levels of p53 in response to DNA damage. Although studies have shown that Mus81 plays an important role in the response of cells to DNA-damaging agents, À/À MEFs. Cells were treated with 0, 1, or 10 Ag/mL of MMC for 24 h, and viability was assessed by trypan blue staining. Columns, mean of three independent experiments; bars, SD.
evidence describing the molecular mechanisms that underlie Mus81-mediated DNA repair is lacking (9, 18, 20) . As such, we first addressed if Mus81 expression is altered in response to DNA damage by examining the effect of the ICL agent MMC on MEFs (Fig. 1A) . Western blot analysis showed that Mus81 expression levels remained unchanged in cells treated with 10 Ag/mL MMC for 4, 8, or 24 h. To confirm that the MMC did induce genotoxic stress in the treated MEFs, we examined the expression of p53 as it is upregulated in response to MMC-induced damage (22) . Elevated levels of p53 were observed 24 h after treatment with 10 Ag/mL MMC, confirming that the MMC was inducing a damage response.
To assess the effect of Mus81 mutation on p53 activation, we generated Mus81 In accordance with our previous study (18) , Mus81 À/À MEFs displayed increased cellular sensitivity to MMC (P = 0.03 for 10 Ag/mL; Fig. 1D ). Our data suggest that the increased activation of p53 observed in Mus81 À/À cells following MMC treatment plays an important role in the ICL hypersensitivity of Mus81-deficient cells. Combined p53 and Mus81 deficiency leads to female embryonic lethality. Mus81-deficient mice are predisposed to developing lymphomas presumably due to elevated levels of genomic instability, a hallmark feature of carcinogenesis. However, cancer involves multiple genetic alterations, including loss of cellular checkpoints (23) . We hypothesized that the p53 tumor suppressor pathway plays an important role in suppressing the genomic instability and tumorigenesis in Mus81-deficient mice and in the hypersensitivity of Mus81-deficient cells to ICL-induced DNA damage.
To identify the functional interactions between p53 and Mus81, double-knockout mice deficient for Mus81 and p53 were generated. Surprisingly, our crosses to generate Mus81 +/À p53
and Mus81 À/À p53 À/À mice did not yield the expected Mendelian ratios ( Supplementary Fig. S2A ). The number of Mus81
offspring (47 mice) was much lower than expected (86 mice). Of the 47 offspring, only 3 were females, indicating that the observed decreased viability of Mus81
p53 À/À mice was female specific (P < 0.001; Supplementary Table S1 ). Similarly, we observed a Previous studies have shown that loss of p53 results in a reduction of female progeny (10-30% depending on background) due to a variety of developmental abnormalities (24, 25) . From our double heterozygote crossings (Mu81 Fig. S3 ). The effect of dual loss of p53 and Mus81 on the in vitro proliferative capacity of T and B cells derived from adult mice was also assessed. No significant differences were observed in the activation-induced proliferation of T and B cells from Mus81 À/À p53 À/À mice when compared with single mutant and and WT cells ( Fig. 2A and B) . These data indicate that combined loss of Mus81 and p53 in male mice does not affect their embryonic development or the development of their immune system. In addition, combined loss of Mus81 and p53 does not alter the proliferative capacities of T and B cells derived from adult males.
Mus81 is dispensable for the response to ;-irradiationinduced DNA damage. p53 is critical for initiating cell cycle arrest and apoptosis in response to ionizing radiation (26) . We previously reported that Mus81 mutation does not impair the cellular response to g-irradiation-induced DNA damage (18) . To investigate the effect of combined loss of Mus81 and p53 in g-irradiation sensitivity, we assessed the viability of lymphocytes 12 h after irradiation using 7-AAD staining (Fig. 2C) . As expected, p53 À/À lymphocytes were highly resistant to g-irradiation compared with WT cells. Mus81-null cells displayed a modest but not significant sensitivity to g-irradiation compared with WT cells (P > 0.1).
tion resistance when compared with p53 À/À cells. These findings
show that Mus81 does not play a significant role in cellular responses to g-irradiation and its inactivation does not impair the resistance of p53 À/À cells to g-irradiation-induced DNA damage.
Loss of p53 rescues the MMC sensitivity of Mus81-deficient cells. Mus81 deficiency increases sensitivity to DNA-damaging agents in yeast and mammals (8, 9, (18) (19) (20) . In particular, loss of mammalian Mus81 results in hypersensitivity to MMC. We have shown that MMC-induced DNA damage results in elevated levels and activation of p53 in Mus81 À/À cells (Fig. 1A) . To elucidate the requirement of p53 for the DNA damage sensitivity of Mus81
À/À cells, we examined the response of Mus81
Because MEFs can lose cellular checkpoints and become immortalized during in vitro culturing, we did colony forming assays in the presence or absence of MMC using primary bone marrow cells isolated from 6-week-old WT, Mus81
, p53 À/À , and
À/À p53 À/À mice. Colony formation was assessed at day 10 of culture and colony numbers were normalized to untreated controls to determine the sensitivity to MMC (Fig. 2D ). Mus81-deficient bone marrow cells were found to be 6-fold more sensitive to MMC than WT cells (P < 0.01; colony survival: Role of p53 in the G 2 arrest of MMC-treated Mus81 À/À cells. Characterization of tumors was done by examination of cellular morphology and staining of tissue sections with cell-and proliferation-specific markers. Similar to our previous study (18) , the majority of sick Mus81 À/À mice that were examined were found to be afflicted with T-cell or B-cell lymphomas (8 of 12, 66%; Supplementary Table S2 ). As has been described previously (27) , p53 À/À mice predominantly developed thymic lymphomas (10 of 12, 83%). Interestingly, the combined loss of Mus81 and p53 led to a unique tumor spectrum, as 64% of Mus81 Table S2 ; Fig. 5B ). In addition, Mus81 À/À p53 À/À mice also developed T-cell or B-cell lymphomas, carcinomas, and thymic lymphomas that are associated with inactivation of Mus81 or p53 (Supplementary Table S2 ; Fig. 5C, D, and H) . Loss of one allele of Mus81 in a p53-null background did not decrease tumor latency in comparison with p53 À/À mice (P > 0.1; Fig. 5A ) but did alter tumor
predominately developed sarcomas (7 of 12, 58%; Supplementary  Table S2 ; Fig. 5B and C) , indicating that loss of one allele of Mus81 is sufficient for increasing the predisposition of p53 À/À mice to sarcomas (P < 0.01). Southern blot analysis of the Mus81 locus was done on three sarcomas isolated from Mus81 Supplementary Fig. S4 ). We did not observe any gross genomic alterations or loss of the Mus81 allele, indicating that loss of heterozygosity (LOH) is not essential for the sarcoma development in Mus81 +/À p53 À/À -mutant background.
Combined loss of Mus81 and p53 not only resulted in decreased tumor latency and changes in the tumor spectrum but also promoted the incidence of multiple tumors (P < 0.01; Fig. 6 ). Table S2 ; Fig. 6A-C) . Similarly, Mus81 +/À p53 À/À mice (6 of 12, 50%) also had an increased incidence of multiple tumors, indicating that biallelic expression of Mus81 is required for the suppression of multiple independent tumors in a p53-null background.
Discussion
Previous studies have shown that Mus81 plays an important role in the repair of ICL-induced structures, such as stalled replication forks, primarily in the late S phase and G 2 phase of the cell cycle (12, 20, 28) . The role of p53 in irradiation-induced cell cycle checkpoints and DSB repair responses has been well documented. However, the role of p53 in responding to stalled replication forks remains poorly characterized. Elucidating the tumor suppressor functions of p53 in the response to stalled replication forks is of significant importance, as defective repair can predispose for cancer and ICL agents, such as MMC, are frequently used for cancer therapy.
To examine the cooperativity of Mus81 and p53 in DNA repair responses and tumorigenesis, we generated Mus81 (18, 19) . In this study, we have examined the role that p53 plays in mediating the MMC sensitivity of Mus81-deficient cells and have found that Mus81 À/À cells display elevated levels of p53 in response (18) . September 15, 2007 Research. that loss of a single allele of Mus81 results in an f50% reduction in protein levels and spontaneous genomic instability and tumor susceptibility (18) . Based on our findings in this study, we speculate that a gene dosage reduction of Mus81 in p53-null mice promotes the genetic alterations required for sarcoma development. Several recent studies have indicated that p53 plays an important role in the repair of stalled replication forks (31) (32) (33) . In fact, Subramanian and Griffith (34) have shown that cancerderived p53 mutants have weaker binding to stalled replication forks. Because Mus81 is able to efficiently resolve stalled replication forks in vitro, it is possible that Mus81 deficiency in vivo results in an increase in the frequency of stalled forks and that the binding of p53 to these structures is critical for repair by alternate pathways. We suggest, in addition to the cell cycle and apoptotic functions of p53, its role in stalled fork repair may play an important role in maintaining genome stability and suppressing tumorigenesis of Mus81 À/À mice. Whereas human studies have identified p53
inactivation as the most common genetic alteration leading to sarcoma formation (35) , no studies have yet linked mutation of Mus81 or other molecules involved in ICL repair with sarcoma formation. We have identified a novel role for Mus81 as a critical haploinsufficient tumor suppressor that collaborates with p53 in suppressing sarcoma formation. Furthermore, our data warrant investigation of the collaborative roles of human Mus81 and p53 in cancer suppression, which will provide important insight into the molecular mechanisms that underlie sarcoma initiation and progression.
